Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
BIOS Capital Management, LP (CIK 1813845) reported $52.9M across 6 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ACTU ($27.5M, 52.09%), IRD ($16.8M, 31.70%), CGTX ($4.6M, 8.63%), RNTX ($2.6M, 4.87%), LTRN ($1.2M, 2.24%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACTU | ACTUATE THERAPEUTICS INC | $27.5M | 52.09% | 10.0M | Hold |
| 2 | IRD | OPUS GENETICS INC | $16.8M | 31.70% | 3.7M | Hold |
| 3 | CGTX | COGNITION THERAPEUTICS INC | $4.6M | 8.63% | 6.0M | Hold |
| 4 | RNTX | REIN THERAPEUTICS INC | $2.6M | 4.87% | 2.0M | Added |
| 5 | LTRN | LANTERN PHARMA INC | $1.2M | 2.24% | 864,435 | Trimmed |
| 6 | INAB | IN8BIO INC | $248,351 | 0.47% | 167,805 | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31